CSIMarket
 
Scynexis Inc   (SCYX)
Other Ticker:  
 
 
Price: $1.6200 $0.00 0.000%
Day's High: $1.6699 Week Perf: -5.81 %
Day's Low: $ 1.60 30 Day Perf: -21.36 %
Volume (M): 213 52 Wk High: $ 3.87
Volume (M$): $ 344 52 Wk Avg: $2.39
Open: $1.63 52 Wk Low: $1.15



 Market Capitalization (Millions $) 78
 Shares Outstanding (Millions) 48
 Employees 100
 Revenues (TTM) (Millions $) 136
 Net Income (TTM) (Millions $) 72
 Cash Flow (TTM) (Millions $) -24
 Capital Exp. (TTM) (Millions $) 0

Scynexis Inc
Scynexis Inc is a biotechnology company that focuses on developing and commercializing highly innovative therapies to address serious and life-threatening fungal infections. Founded in 2000 and headquartered in Jersey City, New Jersey, USA, Scynexis has an experienced leadership team that is dedicated to advancing medical science and improving the lives of patients worldwide.

Scynexis develops therapies for a wide range of fungal infections, including Candida and Aspergillosis, which are often associated with high morbidity and mortality rates. Their lead product candidate, ibrexafungerp (formerly SCY-078), is a novel antifungal drug that acts by inhibiting the fungal enzyme glucan synthase, which is required for the production of fungal cell walls. Ibrexafungerp has demonstrated that it can provide broad-spectrum activity against a range of fungal species and is expected to have a lower risk of developing drug resistance when compared to other available antifungal agents.

In addition to its lead product candidate, Scynexis has an extensive pipeline of antifungal products in development. They are exploring the potential of using ibrexafungerp to target other types of fungal infections, including those caused by drug-resistant strains. Also, Scynexis has developed a proprietary platform technology for the discovery and development of novel antifungal compounds, which they believe can significantly advance the treatment of severe fungal infections.

Scynexis has been successful in raising significant amounts of capital, enabling it to fund its operations and research activities. Moreover, they have established partnerships with reputable organizations, such as the National Institutes of Health (NIH), to advance their research and develop breakthrough treatments. Their partnerships also extend to commercialization deals with established pharmaceutical companies, such as Jiangsu Hengrui Medicine Co., Ltd. and IMMY Inc.

Overall, Scynexis is a pioneering biotechnology company that is dedicated to advancing the field of antifungal therapy. They aim to provide innovative, effective treatments to patients suffering from serious fungal infections and improve overall patient outcomes. Their commitment to scientific excellence and partnership collaborations make them a leader in the field of antifungal research and development.


   Company Address: 1 Evertrust Plaza Jersey City 7302 NJ
   Company Phone Number: 884-5485   Stock Exchange / Ticker: NASDAQ SCYX
   SCYX is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

SCYNEXIS Unveils Groundbreaking Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference

Published Mon, Jan 29 2024 10:15 PM UTC

SCYNEXIS Presents Promising Preclinical Data on Second Generation Fungerp SCY-247 against MucormycosisJERSEY CITY, N.J., Jan. 29, 2024 - SCYNEXIS, Inc. (NASDAQ: SCYX), a pioneering biotechnology company specializing in innovative medicines to combat challenging-to-treat and drug-resistant infections, unveiled compelling preclinical efficacy data today at the 11th Advances A...

Scynexis Inc

Scynexis Inc. Surpasses Expectations with Remarkable Revenue Growth in Q3 2023

Scynexis Inc, a biotechnology company specializing in innovative medicines to combat challenging and drug-resistant infections, recently presented promising preclinical data on its second-generation fungerp candidate, SCY-247. The data highlighted SCY-247's effectiveness against various fungal pathogens, including echinocandin-resistant Candida and Aspergillus. The presentation occurred at the 11th Congress on Trends in Medical Mycology (TIMM) in Athens, Greece.
While Scynexis Inc witnessed a 13.102% increase in revenue from the previous financial reporting period, reaching $1.76 million between July and September 2023, the company experienced a loss of $-0.04 per share. Despite this, Major Pharmaceutical Preparations companies thrived in the third quarter of 2023. On the other hand, several businesses within the industry have been struggling with diminishing transactions and revenue.

Scynexis Inc

Scynexis Inc Shatters Records with 9,836% Revenue Growth and Turns Losses into Profits

Scynexis Inc Reports Impressive Revenue Growth and Profitability
Scynexis Inc, a major player in the pharmaceutical industry, has recently posted exceptional financial results for its fiscal three months ending June 30, 2023. Despite the challenging market conditions faced by its contemporaries, Scynexis Inc has defied the odds, reporting a staggering revenue growth of 9,836.054% year on year, amounting to $131.45 million.
One of the key highlights of Scynexis Inc's performance is its remarkable improvement in earnings per share (EPS). With EPS at $2.46, the company has managed to turn around its financial performance compared to the previous reporting season when it had a negative EPS of $-0.71 per share. This significant improvement demonstrates Scynexis Inc's ability to generate profits, leading to greater shareholder value.

Scynexis Inc

Scynexis Inc. Achieves Remarkable 64.48% Revenue Surge in Latest Fiscal Period

Scynexis Inc. sees a significant revenue increase in the first quarter of 2023, increasing by 64.48% year on year to a cumulative value of $6 million. This outstanding performance resulted in the company?s revenue per employee growing to $55,340 on a trailing twelve-month basis, a new company high. The company, which currently has 100 employees, has seen its overall ranking deteriorate, from 250 to 251, compared to the previous quarter within the Healthcare sector.
Despite the positive revenue growth, Scynexis Inc. faced an earnings loss of $0.71 per share for the first quarter of 2023. This figure is a significant increase from last year's $0.18 loss per share. Moreover, the company recorded a net loss of $-33.876 million, higher than $-5.451 million a year ago. The revenue for the first quarter 2023 increased by 64.483% to $1.13 million from $0.69 million in the same quarter a year ago. However, revenue fell sequentially from $1.52 million.
The company's financial earnings for the next quarter will be reported on August 14, 2023. Despite challenges faced, the company is positive about its growth and potential in the industry. The healthcare sector is an ever-changing industry that presents new opportunities and challenges and the company is committed to navigating these changes positively.






 

Scynexis Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com